Jazz Pharmaceuticals PLC $JAZZ Stock: Robeco Institutional Asset Management B.V. Cuts Stake

Robeco Institutional Asset Management B.V. cut its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 18.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 96,350 shares of the specialty pharmaceutical company’s stock after selling 21,262 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Jazz Pharmaceuticals were worth $22,307,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp grew its position in Jazz Pharmaceuticals by 44.5% in the 1st quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock worth $317,485,000 after purchasing an additional 517,514 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Jazz Pharmaceuticals by 10.9% in the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after purchasing an additional 99,656 shares during the period. Boston Trust Walden Corp increased its stake in shares of Jazz Pharmaceuticals by 24.1% in the first quarter. Boston Trust Walden Corp now owns 488,661 shares of the specialty pharmaceutical company’s stock valued at $92,381,000 after purchasing an additional 94,750 shares during the period. Systematic Financial Management LP increased its stake in shares of Jazz Pharmaceuticals by 2.6% in the first quarter. Systematic Financial Management LP now owns 407,114 shares of the specialty pharmaceutical company’s stock valued at $76,965,000 after purchasing an additional 10,237 shares during the period. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Jazz Pharmaceuticals during the first quarter valued at approximately $60,496,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $214.00 on Friday. The firm has a 50-day moving average price of $236.11 and a 200 day moving average price of $232.83. The firm has a market capitalization of $13.89 billion, a PE ratio of 9.29, a P/E/G ratio of 0.22 and a beta of 0.37. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals PLC has a 52-week low of $128.80 and a 52-week high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.11 billion. During the same period in the previous year, the business posted ($8.25) EPS. The firm’s quarterly revenue was up 15.5% on a year-over-year basis. On average, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 21.59 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of several analyst reports. Canaccord Genuity Group set a $300.00 price objective on Jazz Pharmaceuticals in a research report on Wednesday, August 26th. JPMorgan Chase & Co. increased their price objective on Jazz Pharmaceuticals from $265.00 to $276.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Weiss Ratings upgraded Jazz Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. Wells Fargo & Company raised their target price on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Finally, Piper Sandler lifted their target price on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $290.85.

Insider Activity at Jazz Pharmaceuticals

In other news, EVP Neena Patil sold 1,200 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total value of $289,128.00. Following the completion of the transaction, the executive vice president directly owned 47,671 shares in the company, valued at $11,485,850.74. This trade represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of the stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the completion of the transaction, the executive vice president owned 65,686 shares of the company’s stock, valued at $16,401,794.20. This trade represents a 53.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 100,121 shares of company stock valued at $24,855,802. 4.10% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.